Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | MMP1 | P03956 | 1/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067735 | 0.88 | SLC7A11 (0.79) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| SCHEMBL30758844 | 0.85 | SLC7A11 (0.74) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| SCHEMBL8068293 | 0.85 | SLC7A11 (0.74) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL4514 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL5664970 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL10289061 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL4515 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL29861725 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL487664 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 | |
| Sulfasalazine SCHEMBL31174674 | 0.84 | SLC7A11 (1.00) | SLC7A11LMNAKMT2AMEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177869-A1 | METHODS AND COMBINATIONS FOR MODULATING TOLERANCE TO OPIATES, OPIOIDS OR OPIOID ANALGESICS AND TREATING ACUTE AND CHRONIC PAIN | CHINA MEDICAL UNIVERSITY (TW) | 2021-06-17 | — | — | US | claimed |
| US-20210177869-A1 | METHODS AND COMBINATIONS FOR MODULATING TOLERANCE TO OPIATES, OPIOIDS OR OPIOID ANALGESICS AND TREATING ACUTE AND CHRONIC PAIN | CHINA MEDICAL UNIVERSITY (TW) | 2021-06-17 | — | — | US | disclosed |
| CN-112839679-A | Methods and combinations for modulating tolerance to opiates, opioids or opioid analgesics and treating acute and chronic pain | 中国医药大学 | 2021-05-25 | — | — | CN | disclosed |
| US-20200392084-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | ABU IZZA KHAWLA (US) | 2020-12-17 | — | — | US | disclosed |
| CN-111971272-A | Sulfasalazine salt compositions and methods of use thereof | 库布拉·阿布-伊扎 | 2020-11-20 | — | — | CN | disclosed |
| EP-3694837-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | Abu-Izza, Khawla (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-2950797-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES | GLIALOGIX INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10398713-B2 | Compositions and methods for the treatment of neurodegenerative and other diseases | Glialogix, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019074908-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | ABU IZZA KHAWLA (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190015431-A1 | Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases | Glialogix, Inc. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9597339-B2 | Compositions and methods for the treatment of neurodegenerative and other diseases | Glialogix, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2950797-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES | Glialogix, Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014121137-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES | Glialogix, Inc. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221321-A1 | Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases | Glialogix, Inc. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-0613468-B1 | Substituted salicylic acids for the treatment of autoimmune diseases | PHARMACIA & UPJOHN AB (SE) | 2000-07-12 | — | — | EP | disclosed |
| US-5556855-A | TREATMENT OF AUTOIMMUNE DISEASES | PHARMACIA AB (SE) | 1996-09-17 | — | — | US | disclosed |
| US-5403930-A | Chemical intermediate for drugs used in autoimmune diseases | PHARMACIA AB (SE) | 1995-04-04 | — | — | US | disclosed |
| EP-0613468-A1 | NOVEL SUBSTITUTED SALICYCLIC ACIDS | Pharmacia & Upjohn Aktiebolag (SE) | 1994-09-07 | — | — | EP | disclosed |
| US-5302718-A | Used for treating autoimmune diseases | KABI PHARMACIA AB (SE) | 1994-04-12 | — | — | US | disclosed |
| WO-1993010094-A1 | NOVEL SUBSTITUTED SALICYCLIC ACIDS | KABI PHARMACIA AB (SE) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392084-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | STS, SCLY, SCN5A | SLC7A11 31/4885LMNA 4040/4885KMT2A 1557/4885 |
| US-20190015431-A1 | Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases | SMN1; SMN2, HTT, TPMT | SLC7A11 736/4885LMNA 4022/4885KMT2A 458/4885 |
| US-20140221321-A1 | Compositions and Methods for the Treatment of Neurodegenerative and Other Diseases | SMN1; SMN2, HTT, TPMT | SLC7A11 736/4885LMNA 4022/4885KMT2A 458/4885 |
| US-10398713-B2 | Compositions and methods for the treatment of neurodegenerative and other diseases | SMN1; SMN2, HTT, TPMT | SLC7A11 736/4885LMNA 4022/4885KMT2A 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.